A method and article to treat ocular disease with Cyclosporin A alone or with compounds related to Cyclosporin A for intraocular injection or implantation. Treatment does not result in ocular toxicity and encompasses age related macular degeneration, retinitis pigmentosa, and retinopathy such as dia
A method and article to treat ocular disease with Cyclosporin A alone or with compounds related to Cyclosporin A for intraocular injection or implantation. Treatment does not result in ocular toxicity and encompasses age related macular degeneration, retinitis pigmentosa, and retinopathy such as diabetic retinopathy.
대표청구항▼
The invention claimed is: 1. A method of treating diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition consisting essentially of Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat diabe
The invention claimed is: 1. A method of treating diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition consisting essentially of Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat diabetic retinopathy or retinitis pigmentosa without substantial toxicity to the patient. 2. The method of claim 1 comprising administering by retrobulbar, intravitreal, intraretinal, or subconjunctival injection. 3. The method of claim 1 wherein injection is subconjunctival at a dose in the range of about 1 ng/ml to about 500 μg/ml, intravitreal at a dose in the range of about 1 μg/0.1 ml to about 1000 μg/0.1 ml, retrobulbar at a dose in the range of about 20 μg/ml to about 1000 μg/ml, or subretinal at a dose in the range of about 1 μg/0.1 ml to about 100 μg/0.1 ml. 4. The method of claim 1 wherein Cyclosporin A is injected at a dose in the range of about 20 μg/ml to about 1000 μg/ml. 5. A method of treating diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition comprising Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat diabetic retinopathy or retinitis pigmentosa without substantial toxicity to the patient. 6. The method of claim 5 comprising administering by retrobulbar, intravitreal, intraretinal, or subconjunctival injection. 7. The method of claim 5 wherein the composition further comprises an immunosuppressant selected from the group consisting of tacrolimus, cyclosphosphamide, sirolimus, atoposide, thiotepa, methotrexate, azathioprine, interferons, infliximab, etanercept, mycophenolate mofetil, 15-deoxyspergualin, thalidomide, glatiramer, leflunomide, vincristine, cytarabine, and combinations thereof. 8. The method of claim 1 wherein Cyclosporin A is provided in at least one of a microsphere, liposome, capsule or polymeric matrix. 9. The method of claim 5 wherein Cyclosporin A is provided in at least one of a microsphere, liposome, capsule or polymeric matrix. 10. A method of treating macular degeneration, diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition comprising Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat macular degeneration, diabetic retinopathy, or retinitis pigmentosa without substantial toxicity to the patient, wherein injection is subconjuctival at a dose in the range of about 1 μg/ml to about 500 μg/ml, intravitreal at a dose in the range of about 1 μg/0.1 ml to about 1000 μg/0.1 ml, retrobulbar at a dose in the range of about 20 μg/ml to about 1000 μg/ml, or subretinal at a dose in the range of about 1 μg/0.1 ml to about 1000 μg/0.1 ml. 11. A method of treating macular degeneration, diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition comprising Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat macular degeneration, diabetic retinopathy, or retinitis pigmentosa without substantial toxicity to the patient, wherein Cyclosporin A is injected at a dose in the range of about 20 μg/ml to about 1000 μg/ml.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (40)
Yat Sun Or ; Tsvetelina Lazarova ; Sophie Binet ; Jianchao Wang, 14-membered macrolides derived from leucomycins.
Nelson, Kevin D.; Romero-Sanchez, Andres A.; Smith, George M.; Alikacem, Nadir; Radulescu, Delia; Waggoner, Paula; Hu, Zhibing, Drug releasing biodegradable fiber implant.
John W. Gibson ; Stacey A. Sullivan ; John C. Middleton ; Arthur J. Tipton, High viscosity liquid controlled delivery system and medical or surgical device.
Gregory, Susan A; Isakson, Peter C; Anderson, Gary, Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin.
Nussenblatt Robert B. (Bethesda MD) Palestine Alan G. (Potomac MD), Method of treating ocular diseases by periocular administration of cyclosporine A or G.
Robinson, Michael R.; Csaky, Karl G.; Yuan, Peng; Sung, Cynthia; Nussenblatt, Robert B.; Smith, Janine A., Ocular therapeutic agent delivery devices and methods for making and using such devices.
Heller Jorge (Woodside CA) Ng Steve Y. W. (San Francisco CA) Penhale Donald W. H. (Menlo Park CA), Polymers containing carboxy-ortho ester and ortho ester linkages.
Heller Jorge (Palo Alto CA) Helwing Robert F. (Sunnyvale CA) Penhale Donald W. (Cupertino CA), Polymers of di- (and higher functionality) ketene acetals and polyols.
Daniel Tuse ; Kristien Mortelmans ; Leslie A. Hokama ; Michael E. Selsted ; Larry L. Chapoy ; Michael H. Quinn, Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial.
Baker Robert K. ; Kayser Frank ; Bao Jianming ; Kotliar Andrew ; Parsons William H. ; Rupprecht Kathleen M., Triterpene derivatives with immunosuppressant activity.
Kleinman, David M.; Nivaggioli, Thierry; Gerritsen, Mary E.; Weber, David A., Formulations and methods for vascular permeability-related diseases or conditions.
Kleinman, David M.; Nivaggioli, Thierry; Gerritsen, Mary E.; Weber, David A., Formulations and methods for vascular permeability-related diseases or conditions.
Kleinman, David M.; Nivaggioli, Thierry; Gerritsen, Mary E.; Weber, David A., Formulations and methods for vascular permeability-related diseases or conditions.
Dor, Philippe J. M.; Mudumba, Sreenivasu; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq; Takhar, Sudeep, Formulations for treating ocular diseases and conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Lee, Bong Hee; Byun, Kyung Hee, Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.